Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis

Carcinoma, Squamous Cell Clinical Trial

— HER-Uro01  

Official title:

Phase II Study of the Pan-HER Inhibitor Dacomitinib (PF-00299804) for Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01728233
• Other study ID #: INT110/12
• Status: Completed
• Phase: Phase 2
• Start date: June 15, 2013
• Est. completion date: September 21, 2018

Study information

• Verified date: May 2021
• Source: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Penile squamous cell carcinoma (SCC) is a very rare disease and prognosis depends primarily on regional lymph-node involvement. Despite the fact that cure can be obtained in patients with low metastatic load (pN1) by monotherapy, combination therapy is required for more advanced cases. Medical treatment options only for advanced or metastatic penile SCC are not very effective so far and the few chances for cure are solely dependent on multimodality treatment, either with surgery or radiation. Based on the observation that the epidermal growth factor receptor (EGFR) is almost invariably expressed in penile SCC and assuming similarities to the SCC of head and neck district, anti-EGFR targeted monotherapy has been investigated with promising early results at Istituto Tumori Milan and University of Texas MD Andreson Cancer Center. These premises lend support to the use of the pan-HER inhibitor dacomitinib for advanced or metastatic penile SCC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: September 21, 2018
• Est. primary completion date: September 21, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients must provide written informed consent

• Eastern Cooperative Oncology Group performance status of at least 1

• Cytologically or histologically proven diagnosis of SCC of the penis

• Uni- or bidimensionally measurable disease as defined by RECIST v1.1 criteria

• Clinical stage N2-3 and/or M1 (TNM 2002)

• Locoregional relapse after prior major surgery/ies (either single or multiple)

• No prior systemic therapy except for the administration of vincristine-bleomycin-methotrexate (VBM) chemotherapy for superficial disease if administered at least 6 months prior to study enrollment

• Adequate bone marrow, liver and renal function

Exclusion Criteria:

• Central nervous system (CNS) metastases or leptomeningeal carcinomatosis

• History of active serious cardiovascular, cerebrovascular, pulmonary co-morbidities

• Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma or any cancer curatively treated > 5 years prior to study entry.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Penile Neoplasms

Intervention

Drug:
• Dacomitinib
PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.

Locations

Country	Name	City	State
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori	Milan

Sponsors (2)

Lead Sponsor	Collaborator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Pfizer

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome measure will be the assessment of response-rate (RR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.	RR (%) = complete response (CR) + partial response (PR), where CR is the disappearance of all target lesions (any pathological lymph-nodes must have reduction in short axis to < 10 mm) and PR indicates at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.	2-months
Secondary	To assess the safety and tolerability of the study drug. Incidence, nature and severity of treatment-related adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.		2-months
Secondary	Pathologic complete response (pCR) rate for patients undergoing surgery in the treatment time course.		2-months or longer.
Secondary	Progression-free survival.		2-months.
Secondary	Overall Survival		6-months
Secondary	Variations of the Quality of Life score as assessed with the Edmonton Symptom Assessment Scale (ESAS), validated in Italian language.		2-months.